ANRO · Alto Neuroscience Inc
United States · RS rating 33 · As of 2026-10-14
| Price | 21.71 USD |
|---|---|
| 1-day change | -1.7% |
| RS rating (overall / 1M / 3M / 12M) | 33 / 7 / 19 / 98 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 32 / 35 / 27 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +18.8% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +40.8% |
| Market cap (USD) | $901.2M |